By Reuters Staff 1 Min Read FILE PHOTO: Vials labelled "COVID-19 Coronavirus Vaccine" and sryinge are seen in front of displayed Johnson&Johnson logo in this illustration taken, February 9, 2021. REUTERS/Dado Ruvic/Illustration/File Photo (Reuters) - Emergent BioSolutions Inc said late on Sunday that a key U.S. agency has increased an order, related to the manufacturing of Johnson & Johnson’s COVID-19 vaccine, by $23 million. The amount will be used to purchase biologics equipment specific to J&J’s vaccine and support the potential manufacturing expansion at the company’s Baltimore Bayview facility, the company said in a statement. Emergent also said that it will agree to a mutual ramp down of manufacturing of AstraZeneca Plc’s COVID-19 vaccine bulk drug substance.